Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?
Savara Inc. received an FDA refusal to file for Molbreevi's BLA. The FDA requested additional Chemistry, Manufacturing, and Controls (CMC) data. No safety concerns were cited; no additional efficacy studies requested. Savara plans to meet FDA within 30 days to discuss next steps. SVRA stock fell 28.9% to $2.02 following the announcement.
View signal analysis